2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Non-Small-Cell Lung
16
Ovarian Neoplasms
12
Breast Neoplasms
9
Fallopian Tube Neoplasms
6
Carcinoma, Ovarian Epithelial
5
Squamous Cell Carcinoma of Head and Neck
4
Endometrial Neoplasms
4
Neoplasm Metastasis
3
Lung Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Carcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Non Small Cell Lung Carcinoma NSCLC
2
Neoplasms, Unknown Primary
2
Neoplasms
2
NSCLC
2
Melanoma
2
Esophageal Neoplasms
2
Adenocarcinoma
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Unresectable Stage III NSCLC
1
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcopenia
1
Interventions
Cisplatin
161
Fluorouracil
135
Paclitaxel
127
Radiotherapy
125
Oxaliplatin
88
Docetaxel
71
Carboplatin
71
Irinotecan
60
pembrolizumab
57
Leucovorin
57
Capecitabine
57
Radiation
48
Esophagectomy
44
Surgical Procedures, Operative
41
Drug Therapy
38
Neoadjuvant Therapy
28
Cetuximab
25
Nivolumab
24
Bevacizumab
21
camrelizumab
20
Trastuzumab
20
S 1 (combination)
19
Chemoradiotherapy
19
Magnetic Resonance Spectroscopy
18
Epirubicin
16
Albumin-Bound Paclitaxel
16
Blood Specimen Collection
15
tislelizumab
14
Taxes
14
Radiotherapy, Intensity-Modulated
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
CP protocol
×
Clear all
NCT01404156
2024-08-28
POWERRANGER
CancerCare Manitoba
Phase 2/3
Completed
29 enrolled
NCT02924909
2018-03-20
QUIMERA
Instituto Nacional de Cancer, Brazil
Phase 2
Unknown
50 enrolled